Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis
In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been shown to be effective and safe in several studies. Their side effects are...
Saved in:
Main Authors: | Eduardo V. Mendes Roncada (Author), Victoria Romanini Brambilla (Author), Beatriz Freitas Filitto (Author), Mariana Pirajá Genta (Author), Marilda Ap. M. Morgado de Abreu (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2021-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Secukinumab-induced paradoxical palmoplantar pustular psoriasis
by: Yıldız Gürsel Ürün, et al.
Published: (2022) -
Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis
by: Galina Balakirski, et al.
Published: (2023) -
Paradoxical pustular psoriasis in a patient with spondyloarthritis treated with secukinumab
by: Daniela Anghel, et al.
Published: (2023) -
Paradoxical flare of psoriasis, psoriatic spondyloarthritis, and psoriatic uveitis after switching from infliximab to secukinumab
by: Peiqi Su, et al.
Published: (2017) -
Anetoderma: an alert for antiphospholipid antibody syndrome,
by: Mariana Piraja Genta, et al.
Published: (2020)